CD52 and follicular lymphoma: Building on UCART19′s initial success, Cellectis, Allogene and Servier begun investigating the use of TCR and CD52 KO CAR T cells in conjunction with an anti-CD52 recombinant antibody to treat relapsed or refractory large B cell lymphoma or follicular lymphoma.